Can We Miss Pigmented Lesions in Psoriasis Patients?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01053819
Recruitment Status : Completed
First Posted : January 21, 2010
Results First Posted : August 22, 2012
Last Update Posted : February 23, 2018
Information provided by (Responsible Party):
Boni Elewski, MD, University of Alabama at Birmingham

Brief Summary:
In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However, successful systemic treatment and subsequent clearing of psoriatic plaques may allow clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of early identification and treatment of suspicious lesions such as nonmelanoma skin cancer and malignant melanoma.

Condition or disease Intervention/treatment Phase
Psoriasis Melanoma Non-melanoma Skin Cancer Drug: etanercept Phase 4

Detailed Description:
No further description is desired.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Can We Miss Pigmented Lesions in Psoriasis Patients?
Study Start Date : September 2007
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Etanercept

Arm Intervention/treatment
Experimental: Etanercept
open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
Drug: etanercept
Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
Other Name: Enbrel

Primary Outcome Measures :
  1. The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. [ Time Frame: Patients will complete study within 6 months. ]

Secondary Outcome Measures :
  1. A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria [ Time Frame: Patients will complete the study within 6 months ]
    The data for this Outcome was not collected and due to the length of time, the records have been destroyed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Diagnosis of moderate to severe plaque psoriasis identified by a BSA greater than or equal to 10% and a Psoriasis Area and Severity Index score greater than or equal to 12
  2. Age 19 years or above
  3. Fitzpatrick skin type I, II or III
  4. Candidate for systemic treatment in the opinion of the investigator
  5. Willingness to undergo treatment with Enbrel as outlined above
  6. Negative pregnancy test (urine or serum β-Human Chorionic Gonadotrophin ) before the first dose of study drug in all women (except those surgically sterile, or at least 5 years postmenopausal).
  7. Negative Tuberculosis skin test at entry into the study or a negative screening x-ray in inconclusive Purified Protein Derivative reading (borderline, reactive but non-diagnostic) or in prior bacille Calmette-Guerin inoculated subjects.
  8. Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study
  9. Subject or designee must have the ability to self-inject study medication or have a care giver at home who can administer subcutaneous injections
  10. Must be able and willing to give written informed consent and comply with the requirements of the study protocol and must authorize release and use of protected health information

Exclusion Criteria:

  1. Serum creatinine > 3.0 mg/dL (265 micromoles/L)
  2. Serum potassium < 3.5 mmol/L or > 5.5 mmol/L
  3. Serum alanine aminotransferase or Aspartate transaminase > 3 times the upper limit of normal for the Lab
  4. Platelet count < 100,000/mm3
  5. White blood cell count < 3,000 cells/mm3
  6. Hemoglobin, hematocrit, or red blood cell count outside 30% of the upper or lower limits of normal for the Lab
  7. Systemic therapy use (e.g. phototherapy, methotrexate, cyclosporine, oral steroids, systemic biologics) within the previous 4 weeks
  8. Topical therapy use (e.g. topical steroids, vitamin D derivatives) within the previous 2 weeks
  9. Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.
  10. Subjects who have known hypersensitivity to Enbrel or any of its components or who is known to have antibodies to etanercept
  11. Prior or concurrent cyclophosphamide therapy
  12. Concurrent sulfasalazine therapy
  13. Known Human immunodeficiency virus-positive status or known history of any other immunosuppressing disease
  14. Active severe infections within 4 weeks before screening visit, or between the screening and baseline visits
  15. Untreated Lyme disease
  16. Severe comorbidities (diabetes mellitus requiring insulin, CHF of any severity, MI, CVA or TIA within 3 months of screening visit, unstable angina pectoris, uncontrolled hypertension (sitting systolic BP <80 mm Hg or > 160 or diastolic BP > 100 mm Hg), oxygen-dependent severe pulmonary disease, history of cancer within 5 years [other than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer])
  17. History of TB or TB exposure, chronic hepatitis B or hepatitis C, SLE, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy
  18. History of recent alcohol or substance abuse (< 1 year)
  19. Pregnant or lactating females
  20. Use of a live vaccine 90 days prior to, or during this study
  21. Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient
  22. History of non-compliance with other therapies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01053819

United States, Alabama
UAB Dermatology
Birmingham, Alabama, United States, 35233
Sponsors and Collaborators
University of Alabama at Birmingham
Principal Investigator: Boni E Elewski, MD University of Alabama at Birmingham

Responsible Party: Boni Elewski, MD, Principal Investigator, University of Alabama at Birmingham Identifier: NCT01053819     History of Changes
Other Study ID Numbers: F070629011
First Posted: January 21, 2010    Key Record Dates
Results First Posted: August 22, 2012
Last Update Posted: February 23, 2018
Last Verified: January 2018

Keywords provided by Boni Elewski, MD, University of Alabama at Birmingham:
non-melanoma skin cancer

Additional relevant MeSH terms:
Skin Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Skin Diseases, Papulosquamous
Skin Diseases
Neoplasms by Site
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors